299
Views
1
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

A Retrospective Claims Database Study to Clarify Disease Burden of Severe Asthma Patients with Type 2 High or Low Inflammation

ORCID Icon, , , , &
Pages 83-93 | Received 12 Jul 2022, Accepted 04 Dec 2022, Published online: 05 Jan 2023

References

  • Nakamura Y, Tamaoki J, Nagase H, et al. Japanese guidelines for adult asthma 2020. Allergol Int. 2020;69:519–548. doi:10.1016/j.alit.2020.08.001
  • Nagase H, Adachi M, Matsunaga K, et al. Prevalence, disease burden, and treatment reality of patients with severe, uncontrolled asthma in Japan. Allergol Int. 2020;69:53–60. doi:10.1016/j.alit.2019.06.003
  • Sato K, Ohno T, Ishii T, Ito C, Kaise T. The prevalence, characteristics, and patient burden of severe asthma determined by using a Japan health care claims database. Clin Ther. 2019;41:2239–2251. doi:10.1016/j.clinthera.2019.08.015
  • Inoue H, Kozawa M, Milligan KL, Funakubo M, Igarashi A, Loefroth E. A retrospective cohort study evaluating healthcare resource utilization in patients with asthma in Japan. NPJ Prim Care Respir Med. 2019;29:13. doi:10.1038/s41533-019-0128-8
  • Kuruvilla ME, Lee FE, Lee GB. Understanding asthma phenotypes, endotypes, and mechanisms of disease. Clin Rev Allergy Immunol. 2019;56:219–233. doi:10.1007/s12016-018-8712-1
  • Denton E, Price DB, Tran TN, et al. Cluster analysis of inflammatory biomarker expression in the International Severe Asthma Registry. J Allergy Clin Immunol Pract. 2021;9:2680–2688.e7. doi:10.1016/j.jaip.2021.02.059
  • Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention; 2021. Available from: http://www.ginasthma.org. Accessed January, 31, 2022.
  • Soma T, Iemura H, Naito E, et al. Implication of fraction of exhaled nitric oxide and blood eosinophil count in severe asthma. Allergol Int. 2018;67S:S3–S11. doi:10.1016/j.alit.2018.04.003
  • Kimura H, Makita H, Taniguchi N, et al. Determination of the cutoff values of Th2 markers for the prediction of future exacerbation in severe asthma: an analysis from the Hokkaido severe asthma cohort study. Allergol Int. 2021;70:68–73. doi:10.1016/j.alit.2020.09.001
  • Matsusaka M, Fukunaga K, Kabata H, Izuhara K, Asano K, Betsuyaku T. Subphenotypes of type 2 severe asthma in adults. J Allergy Clin Immunol Pract. 2018;6:274–276.e2. doi:10.1016/j.jaip.2017.06.015
  • Tan R, Liew MF, Lim HF, Leung BP, Wong WSF. Promises and challenges of biologics for severe asthma. Biochem Pharmacol. 2020;179:114012. doi:10.1016/j.bcp.2020.114012
  • Kyriakopoulos C, Gogali A, Bartziokas K, Kostikas K. Identification and treatment of T2-low asthma in the era of biologics. ERJ Open Res. 2021;7:00309–2020. doi:10.1183/23120541.00309-2020
  • Humbert M, Beasley R, Ayres J, et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy. 2005;60:309–316. doi:10.1111/j.1398-9995.2004.00772.x
  • Ortega HG, Liu MC, Pavord ID, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014;371:1198–1207. doi:10.1056/NEJMoa1403290
  • FitzGerald JM, Bleecker ER, Nair P, et al. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2016;388:2128–2141. doi:10.1016/S0140-6736(16)31322-8
  • Castro M, Corren J, Pavord ID, et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med. 2018;378:2486–2496. doi:10.1056/NEJMoa1804092
  • Mekov E, Nuñez A, Sin DD, et al. Update on asthma-COPD overlap (ACO): a narrative review. Int J Chron Obstruct Pulmon Dis. 2021;16:1783–1799. doi:10.2147/COPD.S312560
  • Arai H, Ouchi Y, Toba K, et al. Japan as the front-runner of super-aged societies: perspectives from medicine and medical care in Japan. Geriatr Gerontol Int. 2015;15:673–687. doi:10.1111/ggi.12450
  • Tanabe N, Sato S. Narrative review of current COPD status in Japan. J Thorac Dis. 2021;13:3878–3887. doi:10.21037/jtd-20-2263
  • Harada T, Yamasaki A, Fukushima T, et al. Causes of death in patients with asthma and asthma-chronic obstructive pulmonary disease overlap syndrome. Int J Chron Obstruct Pulmon Dis. 2015;10:595–602. doi:10.2147/COPD.S77491
  • Haughney J, Morice A, Blyth KG, et al. A retrospective cohort study in severe asthma describing commonly measured biomarkers: eosinophil count and IgE levels. Respir Med. 2018;134:117–123. doi:10.1016/j.rmed.2017.12.001
  • Hinks TSC, Levine SJ, Brusselle GG. Treatment options in type-2 low asthma. Eur Respir J. 2021;57:2000528. doi:10.1183/13993003.00528-2020
  • Simpson JL, Powell H, Boyle MJ, Scott RJ, Gibson PG. Clarithromycin targets neutrophilic airway inflammation in refractory asthma. Am J Respir Crit Care Med. 2008;177:148–155. doi:10.1164/rccm.200707-1134OC
  • To Y, Taguchi Y, Shimazaki T, et al. Real-world treatment and health care resource use among severe asthma patients in Japan. Respir Investig. 2021;59:464–477. doi:10.1016/j.resinv.2021.02.010
  • Svenningsen S, Nair P. Asthma endotypes and an overview of targeted therapy for asthma. Front Med. 2017;4:158. doi:10.3389/fmed.2017.00158
  • Verini M, Consilvio NP, Pillo SD, et al. FeNO as a marker of airways inflammation: the possible implications in childhood asthma management. J Allergy. 2010;2010:691425. doi:10.1155/2010/691425
  • Azim A, Newell C, Barber C, et al. Clinical evaluation of type 2 disease status in a real-world population of difficult to manage asthma using historic electronic healthcare records of blood eosinophil counts. Clin Exp Allergy. 2021;51:811–820. doi:10.1111/cea.13841
  • Heaney LG, Perez de Llano L, Al-Ahmad M. Eosinophilic and noneosinophilic asthma: an expert consensus framework to characterize phenotypes in a global real-life severe asthma cohort. Chest. 2021;160:814–830. doi:10.1016/j.chest.2021.04.013